A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multi-Site, Parallel-Group, Dose-Finding Trial To Evaluate The Efficacy And Safety Of Different Doses Of Subcutaneously Administered Leo 138559 In Adult Subjects With Moderate-To-Severe Atopic Derm
Posted Date: Nov 6, 2024
- Investigator: Alan Fleischer
- Specialties:
- Type of Study: Drug
The purpose of this study is to compare the efficacy of4 different dose regimens of LEO 138559 with placebo in subjects with moderate-to-severe AD.
Criteria:
Null
Keywords:
Atopic Dermatitis, Eczema
For More Information:
Jordan Sambrookes
NULL
perryj8@ucmail.uc.edu